Apollomics Inc./$APLM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
- Ticker
- $APLM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 14
- Headquarters
- Foster City, United States
- Website
- www.apollomicsinc.com
Apollomics Inc. Metrics
BasicAdvanced
$41M
-
-$3.62
-
-
Price and volume
Market cap
$41M
52-week high
$28.29
52-week low
$12.58
Average daily volume
16K
Financial strength
Current ratio
0.146
Quick ratio
0.09
Long term debt to equity
-0.033
Total debt to equity
-0.197
Interest coverage (TTM)
-61.45%
Profitability
EBITDA (TTM)
-7.169
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,737.77%
Operating margin (TTM)
-1,740.92%
Effective tax rate (TTM)
-0.04%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-67.41%
Return on equity (TTM)
92.30%
Valuation
Price to revenue (TTM)
89.24
Price to book
-3.63
Price to tangible book (TTM)
-3.63
Price to free cash flow (TTM)
-5.234
Free cash flow yield (TTM)
-19.11%
Free cash flow per share (TTM)
-3.554
Growth
Revenue change (TTM)
-94.85%
Earnings per share change (TTM)
-87.19%
3-year revenue growth (CAGR)
-30.53%
3-year earnings per share growth (CAGR)
-66.39%
Apollomics Inc. Financial Performance
Revenues and expenses
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.